Abstract

Glucagon like peptide 1 receptor (GLP1RA) agonists and Dipeptidyl peptidase 4 (DPP4i) inhibitors are drugs commonly used to treat type 2 diabetes. In some situation are the first choice drugs in treatment of this disease. It was demonstrated that glucagon like peptide (GLP1) has proliferative and anti-apoptotic effects on cells of biliary tree as the cholangiocytes [1,2]. Some of large randomised studies have shown the risks of these drugs in hepatobiliary cancers [1].